LUNGevity Foundation Applauds National Campaign to Educate Public about Nation's Number One Cancer Killer, Lung Cancer

LUNGevity collaborates with Pfizer Oncology for new Lung Cancer Profile Campaign


Media Contact:

Victoria Shapiro

WASHINGTON (November 14, 2011) – LUNGevity Foundation today applauded Pfizer’s new national campaign Lung Cancer Profiles, aimed at educating the public about lung cancer and the importance of molecular testing. LUNGevity Foundation, the nation’s largest lung cancer research nonprofit, worked with Pfizer Oncology and other leading lung cancer organizations to create the new campaign. 

“LUNGevity is pleased to have collaborated with Pfizer in its Lung Cancer Profiles campaign,” said Andrea Stern Ferris, President and Chairman of LUNGevity Foundation. “The program complements one of our missions, which is to broaden the conversations about lung cancer and elevate awareness of the nation’s number one cancer killer to the national stage. The importance of molecular profiling closely aligns with our approach of funding biomarker based research for early detection and targeted therapeutics for lung cancer.  We encourage people who have been diagnosed with lung cancer, and whose tumor has not already been tested, to talk to their doctor to see if molecular analysis is appropriate for them.” 

LUNGevity has the largest grants award program for lung cancer research among lung cancer nonprofit organizations in the United States.  In 2011 alone, it has awarded $2 million to fund nine of the most promising lung cancer research proposals in the areas of early detection and targeted therapeutics.

About LUNGevity Foundation

The mission of LUNGevity Foundation is to have a meaningful and immediate impact on improving lung cancer survival rates, ensure a higher quality of life for lung cancer patients, and provide a community for those impacted by lung cancer.

In order to accomplish our mission, LUNGevity funds the most promising research into the early detection and successful treatment of lung cancer. LUNGevity also supports the largest national grassroots lung cancer network, as well as the largest online support community for those affected by lung cancer.

The organization was recently awarded the coveted four-star charity ranking by Charity Navigator, American’s premier charity evaluator based on LUNGevity’s sound fiscal management and commitment to accountability and transparency.

LUNGevity seeks to inspire the nation to commit to ending lung cancer. 

For more information, please visit

About Lung Cancer

  • Lung cancer is the leading cause of cancer death, regardless of gender or ethnicity, or smoking history.
  • Lung cancer impacts one in 14 Americans and kills more than breast, prostate, colorectal, leukemia, and melanoma cancers combined.
  • Lung cancer kills almost twice as many women as breast cancer, and more than twice as many men as prostate cancer.
  • About 55% of all new lung cancer diagnoses are among people who have never smoked or are former smokers.
  • Lung cancer accounts for 14% of all new cancer diagnoses but 27% of all cancer deaths.